Skip to main content

Table 4 Antifungal use among overall patient groups and the adult group by hospital echinocandin restriction

From: Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America

Agent Overall Adults
  Restriction: n = 43 No Restriction: n = 17 p-value (t-ratio or Z-statistic) Restriction: n = 43 No Restriction: n = 17 p-value (t-ratio)
Fluconazole 29.4 (24.5 to 34.3) 28.8 (22.5 to 35) 0.16a (0.48) 39 (34 to 44.2) 36 (24.2 to 45.2) 0.15b (0.8)
Echinocandins 10.9 (8 to 14) 8.6 (4.8 to 12.4) 0.34a (−0.9) 15 (12 to 18.4) 12 (8.5 to 15.7) 0.41b (1.3)
All Antifungals 53.7 (43.1 to 64.4) 49.7 (35.8 to 63.5) 0.3a (−0.08) 76 (63.6 to 89) 66 (44 to 88.4) < 0.001b (0.83)
Invasive Fungal Infections 0.72 (0.55 to 0.9) 0.65 (0.53 to 0.77) 0.538b (1.41) 0.81 (0.65 to 0.97) 0.72 (0.57 to 0.86) 0.3934b (0.57)
  1. Antifungal data presented as mean (95% CI) days of therapy/1000 patient days
  2. Invasive fungal infections data presented as mean (SD) admissions/1000 patient days
  3. a Wilcoxon rank sum compared hospitals restricting echinocandins to those without restrictions
  4. b T-test compared hospitals restricting echinocandins to those without restrictions
  5. Bolded p-values were statistically significant